Advanced Oncotherapy (AVO) – Result of AGM
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed. For further information, please contact: Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: +44 20 3617 8728 Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio […]
Advanced Oncotherapy (AVO) – Financing facility provided by significant shareholders
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a consortium formed by AB Segulah and other investors has made available a £3.9m loan to the Company. The loan will have a two year maturity and a 12% per annum rolled up interest rate. The Segulah group includes AB Segulah, a […]
Advanced Oncotherapy (AVO) – Video and update on progress at Harley Street
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the release of a short video providing an update on the facility at Harley Street and progress made on site. The video features Deconstruct (UK) Limited, principal contractor to the project, and highlights its role in the demolition, excavation and rebuild at […]
Advanced Oncotherapy (AVO) – Final results
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2016, another year of significant development of the Company’s LIGHT system. Highlights: · First successful acceleration of the proton beam through the proton source and Radio Frequency Quadrupole (RFQ) · Successful […]
Advanced Oncotherapy (AVO) – Conversion of Convertible Loan Notes
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company. Further details of the conversion are set […]
DirectorsTalk – Q&A with Professor Steve Myers at Advanced Oncotherapy (AVO).
Advanced Oncotherapy PLC (LON:AVO) subsidiary ADAM S.A. Executive Chairman professor Steve Myers talks to DirectorsTalk about the LIGHT system, it’s likely impact, the design, the progress being made and its future. Q1: Professor Myers, you became Executive Chairman of ADAM S.A. (ADAM), the CERN spin-off and Advanced Oncotherapy’s (AVO’s) subsidiary, in late 2015, and joined AVO’s […]
Advanced Oncotherapy (AVO) – Appointment of Senior Vice-President of Medical Physics
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr. Jonathan Farr as Senior Vice-President of Medical Physics with immediate effect. Dr. Farr will not be taking a Board position. Dr. Farr is a medical physicist working in the treatment of cancer, specialising in proton therapy. His experience […]
AVO – Give me some LIGHT – Wall Street Wires
by Spekulator at Wall Street Wires An introduction. I am an active investor into smaller companies where I see (a) genuine value (b) good management (c) an unusual or groundbreaking product. Mostly a,b and c have to be present and correct, but I will make exceptions. I am invested into companies listed on Nasdaq, London […]
Advanced Oncotherapy (AVO) – Additional financing agreement and new appointment
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces it has made further progress in attracting personnel at the forefront of their field and additional financing. Additional Financing Advanced Oncotherapy announces, that on 12 June 2017, it has entered into a further loan agreement with Blackfinch Investment Ltd, through its […]
Advanced Oncotherapy (AVO) – Technological milestones update
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces further notable progress in the manufacture of its first LIGHT system. Patient Positioning System Multiple components of the treatment room have been manufactured, inspected and tested by the Company’s partner P-Cure Ltd., ahead of their integration to form a complete […]